Clicky

Capricor Therapeutics, Inc.(CAPR) News

Date Title
Jun 26 General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls
Jun 25 No Ad Comm ‘not necessarily positive’ for Capricor, says Roth Capital
Jun 25 Capricor’s deramiocel moves ahead without AdCom, says H.C. Wainwright
Jun 24 Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Jun 21 Capricor Therapeutics announces four-year data from HOPE-2 OLE study
Jun 20 Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Jun 17 Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
Jun 12 Capricor says FDA inspection brought Form 483 with several observations
Jun 11 Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
May 22 Exploring 3 High Growth Tech Stocks In The US Market
May 7 Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
May 6 Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
Apr 17 When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?
Mar 27 High Growth Tech Stocks In The US Market With Promising Potential
Mar 11 Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Mar 10 FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
Feb 17 High Growth Tech Stocks In The United States To Watch
Feb 10 Capricor Therapeutics to Participate in Upcoming Investor Conferences
Jan 3 CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Jan 2 Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy